Cargando…

Three cases of nonmetastatic prostate cancer treated successfully with primary intermittent androgen deprivation therapy over 10 years

We report three cases of nonmetastatic prostate cancer treated effectively with long‐term primary intermittent androgen deprivation (IAD). IAD is not a standard therapy for patients with nonmetastatic prostate cancer. However, based on our experience, we suggest that IAD is one of useful therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shida, Yohei, Hakariya, Tomoaki, Miyata, Yasuyoshi, Sakai, Hideki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378862/ https://www.ncbi.nlm.nih.gov/pubmed/28396761 http://dx.doi.org/10.1002/ccr3.854

Ejemplares similares

Three cases of brain metastasis from castration‐resistant prostate cancer
por: Shida, Yohei, et al.
Publicado: (2019)

Anti-Cancer Effects of Green Tea Polyphenols Against Prostate Cancer
por: Miyata, Yasuyoshi, et al.
Publicado: (2019)

Changes in Lymphangiogenesis and Vascular Endothelial Growth Factor Expression by Neo‐Adjuvant Hormonal Therapy in Prostate Cancer Patients
por: Asai, Akihiro, et al.
Publicado: (2016)

Successful laparoscopic resection of a paraganglioma immediately behind the inferior vena cava and bilateral renal veins
por: Hakariya, Tomoaki, et al.
Publicado: (2019)

Androgen Deprivation Therapy and Cardiovascular Risk in Chinese Patients with Nonmetastatic Carcinoma of Prostate
por: Huang, Gang, et al.
Publicado: (2014)

Stage-specific embryonic antigen-4 is a histological marker reflecting the malignant behavior of prostate cancer
por: Nakamura, Yuichiro, et al.
Publicado: (2019)

Rare case of penile fracture caused by an injury to the crus penis: Delayed repair using the transperineal approach
por: Harada, Junki, et al.
Publicado: (2020)

Intensification of Androgen Deprivation Therapy in High-Risk, Nonmetastatic Prostate Cancer: Lessons From STAMPEDE
por: Gong, Jun, et al.
Publicado: (2022)

Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer
por: Hussain, Arif, et al.
Publicado: (2020)

Androgen deprivation therapy in nonmetastatic prostate cancer patients: Indications, treatment effects, and new predictive biomarkers
por: Fang, Dong, et al.
Publicado: (2019)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

Pheochromocytoma multisystem crisis treated with emergency surgery: a case report and literature review
por: Kakoki, Katsura, et al.
Publicado: (2015)

Benefits of intermittent/continuous androgen deprivation in patients with advanced prostate cancer
por: MURESANU, HORIA
Publicado: (2016)

Intermittent androgen deprivation therapy in patients with prostate cancer: Connecting the dots
por: Abrahamsson, Per-Anders
Publicado: (2017)

Composite pheochromocytoma of the adrenal gland: a case series
por: Shida, Yohei, et al.
Publicado: (2015)

Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial
por: D'Amico, Anthony V., et al.
Publicado: (2021)

Association between medical androgen deprivation therapy and long‐term cardiovascular disease and all‐cause mortality in nonmetastatic prostate cancer
por: Forster, Rachel B., et al.
Publicado: (2022)

Prostate-specific antigen dynamics predict individual responses to intermittent androgen deprivation
por: Brady-Nicholls, Renee, et al.
Publicado: (2020)

Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials
por: Ma, Ting Martin, et al.
Publicado: (2023)

Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy
por: Maru, Shintaro, et al.
Publicado: (2018)

Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2019)

AB37. The combination of I brachytherapy with intermittent androgen deprivation in treating locally advanced prostate cancer
por: Huang, Yi
Publicado: (2014)

Intermittent androgen deprivation therapy: recommendations to improve the management of patients with prostate cancer following the GRADE approach
por: Bonfill, Xavier, et al.
Publicado: (2018)

Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors
por: Saad, Fred, et al.
Publicado: (2021)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

Prostate cancer, insulin, and androgen deprivation therapy
por: Stattin, P, et al.
Publicado: (2003)

Nonmetastatic Castration-Resistant Prostate Cancer
por: Hong, Jun Hyuk, et al.
Publicado: (2014)

Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
por: Chen, Mengqian, et al.
Publicado: (2010)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Cardiometabolic Complications after Androgen Deprivation Therapy in a Man with Prostate Cancer: Effects of 3 Years Intermittent Testosterone Supplementation
por: Aversa, Antonio, et al.
Publicado: (2012)

Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis
por: Botrel, Tobias Engel Ayer, et al.
Publicado: (2014)

Intermittent chemotherapy in metastatic androgen-independent prostate cancer
por: Beer, T M, et al.
Publicado: (2003)

Reply: Prostate cancer, insulin and androgen deprivation therapy
por: Lehrer, S
Publicado: (2003)

Androgen deprivation therapy for prostate cancer and risk of dementia
por: Robinson, David, et al.
Publicado: (2019)

Androgen deprivation therapy in high risk prostate cancer
por: Van Dams, Ritchell, et al.
Publicado: (2019)

Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer
por: Corona, Giovanni, et al.
Publicado: (2021)

Improving intermittent androgen deprivation therapy: lessons learned from basic and translational research
por: Parikh, Rahul A, et al.
Publicado: (2014)

Intermittent Androgen Suppression: Estimating Parameters for Individual Patients Based on Initial PSA Data in Response to Androgen Deprivation Therapy
por: Hirata, Yoshito, et al.
Publicado: (2015)

Impact of Androgen Deprivation on Oxidative Stress and Antioxidant Status in Nigerian Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy
por: Bassey, Iya Eze, et al.
Publicado: (2020)

Initial 3-month dynamics of dehydroepiandrosterone sulfate can predict responsiveness to primary androgen deprivation therapy in patients with metastatic prostate cancer
por: Yano, Akihiro, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qlqifeea6pq4919b1n6mk2541l